Moneyview IPO
Latest news, explainers and analysis on Moneyview IPO. Tracking 5 stories on Arth Vani.
Connected in the graph
Latest on Moneyview IPO
IPOBreakingMoneyview IPO Subscribed 66.57x, Grey Market Premium at ₹13
The initial public offering (IPO) of Moneyview, a fintech company, was significantly oversubscribed by 66.57 times. The Grey Market Premium (GMP) for Moneyview shares currently stands at ₹13, indicating potential listing gains for investors.
IPOBreakingMoneyview IPO Sees 98x Oversubscription, GMP Suggests 41% Gain; Allotment & Listing Nearing
The Moneyview Initial Public Offering (IPO) witnessed an overwhelming response, being oversubscribed 98 times. This makes it the third largest ₹1,000 crore issue to date. Unofficial Grey Market Premium (GMP) indicates a potential listing gain of 41% for investors, with allotment and listing dates approaching soon.
IPOBreakingMoneyview IPO Allotment Status Expected Soon: How to Check and What it Means
The allotment status for the Moneyview IPO is anticipated shortly. Investors who applied for the initial public offering will soon be able to check if they have been allocated shares, with grey market premium (GMP) and listing details also being tracked closely.
IPOBreakingMoneyview IPO to Open on September 24: Price Band Set at ₹32-34 Per Share
Fintech unicorn Moneyview has announced its initial public offering (IPO) details, setting a price band of ₹32 to ₹34 per share. The issue is scheduled to open for public subscription on September 24, marking a significant milestone for the digital lending platform.
IPOBreakingMoneyview Trims IPO Valuation Target to $624 Million; Accel-Backed Fintech Files Papers
Bengaluru-based fintech startup Moneyview has filed for an Initial Public Offering (IPO) seeking a valuation of approximately $624 million (₹5,200 crore). The company has significantly scaled down its valuation expectations compared to earlier internal estimates as it prepares to list on Indian exchanges.
IPO investments are subject to market risk and allotment. Read the RHP / prospectus before applying; grey-market premium (GMP) is unofficial and unreliable. Some listings may be sponsored. Not investment advice.